Zhi-fan Zeng

State Key Laboratory Of Oncology In South China, 651 Dongfeng Road East
Guangzhou, 510060, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Final Results of a Phase III Trial.

Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Final Results of a Phase III Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 19, 2026

Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Initial Results of a Phase III Trial.

Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Initial Results of a Phase III Trial.

Journal: Annals of surgery

Published: December 20, 2022

High dose chemoradiotherapy increases chance of organ preservation with satisfactory functional outcome for rectal cancer.

High dose chemoradiotherapy increases chance of organ preservation with satisfactory functional outcome for rectal cancer.

Journal: Radiation oncology (London, England)

Published: December 07, 2021

Comprehensive treatment experience of anal squamous cell carcinoma from a tertiary cancer center in South China.

Comprehensive treatment experience of anal squamous cell carcinoma from a tertiary cancer center in South China.

Journal: Cancer medicine

Published: June 18, 2021

Serum apolipoprotein B to apolipoprotein A-I ratio is an independent predictor of liver metastasis from locally advanced rectal cancer in patients receiving neoadjuvant chemoradiotherapy plus surgery.

Serum apolipoprotein B to apolipoprotein A-I ratio is an independent predictor of liver metastasis from locally advanced rectal cancer in patients receiving neoadjuvant chemoradiotherapy plus surgery.

Journal: BMC cancer

Published: May 03, 2021

Neoadjuvant chemoradiotherapy in patients with unresectable locally advanced sigmoid colon cancer: clinical feasibility and outcome.

Neoadjuvant chemoradiotherapy in patients with unresectable locally advanced sigmoid colon cancer: clinical feasibility and outcome.

Journal: Radiation oncology (London, England)

Published: February 01, 2021

Serum Apolipoprotein A-I Predicts Response of Rectal Cancer to Neoadjuvant Chemoradiotherapy.

Serum Apolipoprotein A-I Predicts Response of Rectal Cancer to Neoadjuvant Chemoradiotherapy.

Journal: Cancer management and research

Published: January 19, 2021

Neoadjuvant chemoradiotherapy for patients with unresectable radically locally advanced colon cancer: a potential improvement to overall survival and decrease to multivisceral resection.

Neoadjuvant chemoradiotherapy for patients with unresectable radically locally advanced colon cancer: a potential improvement to overall survival and decrease to multivisceral resection.

Journal: BMC cancer

Published: December 17, 2020

Beneficiaries of radical surgery among clinical complete responders to neoadjuvant chemoradiotherapy in rectal cancer.

Beneficiaries of radical surgery among clinical complete responders to neoadjuvant chemoradiotherapy in rectal cancer.

Journal: Cancer science

Published: December 04, 2020

A Genotype Signature for Predicting Pathologic Complete Response in Locally Advanced Rectal Cancer.

A Genotype Signature for Predicting Pathologic Complete Response in Locally Advanced Rectal Cancer.

Journal: International journal of radiation oncology, biology, physics

Published: July 16, 2020

The watch-and-wait strategy versus surgical resection for rectal cancer patients with a clinical complete response after neoadjuvant chemoradiotherapy.

The watch-and-wait strategy versus surgical resection for rectal cancer patients with a clinical complete response after neoadjuvant chemoradiotherapy.

Journal: Radiation oncology (London, England)

Published: May 21, 2020

The high pCR rate of sandwich neoadjuvant treatment in locally advanced rectal cancer may translate into a better long-term survival benefit: 5-year outcome of a Phase II clinical trial.

The high pCR rate of sandwich neoadjuvant treatment in locally advanced rectal cancer may translate into a better long-term survival benefit: 5-year outcome of a Phase II clinical trial.

Journal: Cancer management and research

Published: October 24, 2018

Showing 1-12 of 26

Last Updated: 09/26/2026